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Abstract
Background: During trials that span decades, new evidence including progress in statistical methodology, may
require revision of original assumptions. An example is the continued use of a constant-effect approach to analyse
the mortality reduction which is often delayed in cancer-screening trials. The latter led us to re-examine our
approach for the upcoming primary mortality analysis (2020) of long-term follow-up of the United Kingdom
Collaborative Trial of Ovarian Cancer Screening (LTFU UKCTOCS), having initially (2014) used the proportional
hazards (PH) Cox model.
Methods: We wrote to 12 experts in statistics/epidemiology/screening trials, setting out current evidence,
the importance of pre-specification, our previous mortality analysis (2014) and three possible choices for the follow-
up analysis (2020) of the mortality outcome: (A) all data (2001–2020) using the Cox model (2014), (B) new data
(2015–2020) only and (C) all data (2001–2020) using a test that allows for delayed effects.
Results: Of 11 respondents, eight supported changing the 2014 approach to allow for a potential delayed effect
(option C), suggesting various tests while three favoured retaining the Cox model (option A). Consequently, we
opted for the Versatile test introduced in 2016 which maintains good power for early, constant or delayed effects.
We retained the Royston-Parmar model to estimate absolute differences in disease-specific mortality at 5, 10, 15
and 18 years.
Conclusions: The decision to alter the follow-up analysis for the primary outcome on the basis of new evidence
and using new statistical methodology for long-term follow-up is novel and has implications beyond UKCTOCS.
There is an urgent need for consensus building on how best to design, test, estimate and report mortality
outcomes from long-term randomised cancer screening trials.
Trial registration: ISRCTN22488978. Registered on 6 April 2000.
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Background
Randomised controlled trials (RCT) are the cornerstone
of the evidence base for clinical management of millions
of patients across the world. RCTs evaluating the mor-
tality impact of cancer screening typically involve large
numbers of participants followed up over many years,
sometimes decades. The general rule in clinical trials is
strict adherence to the statistical analysis plan specified
prior to unblinding and analysis of outcome data. Some-
times, during continued long-term follow-up of these
trials, new understanding based on evidence from other
trials and new analytical methods may require re-
evaluation of the analysis plan.
One important example is the accumulating evidence
in cancer-screening trials of a delay of several years
before a mortality reduction is observed between the
screen and control arms [1–3]. Almost all the cancer-
screening trials, breast [4–14], prostate, colorectal, and
lung [15–31] in their graphic representation of disease-
specific mortality over time have reported a delayed dif-
ference (if present) between screen and control arms
(Table 1). Most have an initial time window in the first
several years after start of screening during which there
is little or no mortality reduction, followed by one in
which the reduction becomes evident [2]. These findings
are in keeping with our understanding of how screening
works. It reduces deaths by detecting cancers early,
before they reach an incurable state. It is less likely to
prevent cancer deaths occurring in the early years post
randomisation as there is little chance to detect these
cancers sufficiently early in their natural history.
However, almost none of these cancer–screening trials
have used analytical methods which formally allow for a
non-constant effect (non-proportional hazards). All have
described the screening effect using relatively simple
methods, usually a single Poisson-based rate ratio (RR)
[4, 12, 24, 30, 34, 35] or Cox model with a single hazard
ratio (HR) estimate [18, 22]. A single HR is only appro-
priate if the reduction in hazard rates is relatively imme-
diate and constant over time. In screening trials, such
estimates cannot reliably describe the changing effects of
screening on mortality over time.
Alongside, new analytical methods have been devel-
oped for trials lacking treatment proportionality. Tests
that combine evidence from more than one aspect of the
data have gained popularity as a way to mitigate the
effects of potential but unknown non-proportionality of
hazards, although some may work best in a specific sce-
nario. The “joint test” appears in simulations to be pref-
erentially beneficial under late effects [38, 39] whilst the
“combined test” appears to be preferentially beneficial
under early effects [40, 41]. Another recent addition is
the Versatile test [42], which seeks to cover all bases by
combining three (weighted) log-rank tests giving good
power for the test under early effects, proportional
hazards (PH) and late effects, respectively. These tests
are likely better suited than the Cox model for analysis
of outcomes which are non-proportional across the
duration of a trial.
In the United Kingdom Collaborative Trial of Ovarian
Cancer Screening (UKCTOCS) too, the initial mortality
analysis in 2014 used a PH Cox model and reported an
average mortality reduction estimate. However, given
the growing external evidence, there have been extensive
discussions within the UKCTOCS trial committees to
ensure the outcome data is analysed appropriately. We
believe that this issue will be important for any long-
term cancer screening trial. The Cox model, while valid,
could be viewed as restrictive and failing to utilise the
most appropriate analytical approach, given the delayed
mortality reductions seen in many screening trials across
a range of cancers (Table 1) [14, 17, 24, 31]. Further-
more, retention of the Cox model based on pre-
specification may result in suboptimal interpretation of
UKCTOCS data and therefore an abrogation of our re-
sponsibility to the huge collective investment by the trial
volunteers, the funding agencies, charities, the National
Health Service (NHS), researchers and most importantly
women who develop ovarian cancer in the future. This
is balanced by a concern that changes to the 2014 ana-
lysis plan could be controversial and lead to criticism of
cherry-picking methodology that gives the “best” test
result.
Many trialists may face similar dilemmas, when new
evidence suggests that trial design, conduct or analysis
may need to be amended. Decisions are often made by
the Trial Management Committee (TMC) with input
from independent oversight bodies such as a Trial
Steering (TSC) or Scientific Advisory (SAC) Commit-
tees. We report on the process we undertook in UKC-
TOCS to re-examine our approach for the upcoming
analysis (2020) of the primary mortality outcome at the
end of extended follow-up and how we addressed the
issue of delayed effects.
Methods
Between 2001 and 2005, 202,638 postmenopausal
women aged 50–74 were recruited to UKCTOCS. They
were randomised to screening using a longitudinal
serum CA125 algorithm (multimodal group, MMS, 50,
640), transvaginal ultrasound (ultrasound group, USS,
50,639) or no screening (control group, C, 101,279) as
described previously [43–45]. Women in the screen
groups underwent screening until the end of 2011 and
received a median of nine annual screens. At median
follow-up of 11.1 years (administrative censorship 31
Dec 2014), a higher proportion of women were diag-
nosed with low-volume (stages I, II and IIIa) tubo-
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ovarian cancer in the MMS (40%; p < 0.0001) compared
to the C (26%) group. The Cox model indicated a trend
to mortality reduction in favour of MMS (HR 0.85;
95% CI 0.70–1.03, p = 0.10) and USS (HR 0.89; 95% CI
0.73–1.07, p = 0.21), which was not statistically signifi-
cant at the 5% level. A Royston-Parmar (RP) flexible
parametric model showed that HR varied over time. In
the MMS group, it was 0.92 (95% CI 0.69–1.20) in years
0–7 and 0.77 (95% CI 0.54–0.99) in years 7–14. In the
USS group, it was 0.98 (95% CI 0.74–1.27) in years 0–7
and 0.79 (95% CI 0.58–1.02) in years 7–14 [43]. Follow-
up was extended to 30 June 2020 to assess the long-term
mortality impact (LTFU UKCTOCS) [43, 46]. Final re-
ceipt of death data from the registries is anticipated by
the end of September 2020, with unblinding and analysis
planned for November 2020.
To ensure independent input into our statistical con-
undrum, the TMC proposed seeking the views of a
broad panel of international experts with statistical and
screening trial expertise who had not been involved in
any aspect of UKCTOCS. The process was developed
through detailed discussions with the independent mem-
bers of the TSC. In September 2019, 12 experts (Table 2)
were approached by the Trial Statistician for advice.
They were sent a letter briefly describing UKCTOCS to-
gether with a summary of the current evidence from
other cancer-screening trials, importance of pre-
specification and our 2014 mortality analysis results.
Three potential options for the primary analysis of the
extended follow-up data developed with the TSC were
described sequentially, each including possible pros and
cons, in a neutral manner. These were:
A) Analyse all outcome data (2001–2020) using the PH
Cox model of the original UKCTOCS analysis,
representing the pre-specification viewpoint.
B) Analyse only the outcomes that occurred since the
original censorship (31 December 2014), either
assuming PH or not, to address the view that data
should not be re-used, without formal statistical ac-
commodation for multiple analyses.
C) Model all outcome data using a method of analysis
and model that allows for a late effect of screening
on mortality and reflects current understanding of
cancer-screening trials—a pragmatic evidential ap-
proach. The specific model suggested for (C) was
the RP model [47] as it had been used as a second-
ary analysis method for the 2014 analysis [43].
Experts were asked to critique and state a preference
or suggest another option (Supplementary Materials 1).
Results were collated and summarised based on (1) indi-
cated choice of A, B, C or other and (2) pertinent com-
ments provided.
Results
In total, 12 individuals were contacted from the UK (5),
the USA (5), Canada (1) and Belgium (1) and 11
responded (see acknowledgement). Their anonymised
responses can be found in Table 2 and Supplementary
Table 1.
Eight (73%) of the 11 experts recommended changing
the pre-specified analysis to one that more appropriately
allows for a delayed effect (Table 2). EX4 was not trou-
bled by the shift from a pre hoc to post hoc decision—
Table 2 Summary of experts' choices and their additional suggestions if not in concordance with A, B or C
Expert Expertise Choice Additional suggestions
EX1 Biostatistics, public health A Suggests only include cancers diagnosed from period of intervention.
EX2 Biostatistics, clinical trials and
cancer research
A
EX3 Statistics A Ticked “alternative” but suggested hybrid of A for testing and C for estimation—
interpreted as A




Suggested “number needed to screen”.
EX5 Biostatistics, cancer epidemiology Change
analysis
Did not complete form but indicated choice by email, test based on difference of
restricted mean survival time (RMST).
EX6 Biostatistics and epidemiology Change
analysis
Suggested splitting data into yearly bins and assess HR in each, possibly with smoothing.
Avoid single HR.
EX7 Biostatistics, clinical trials and
cancer research
C Did not complete form but indicated choice by email. Prefers more parsimonious model
with interpretable parameters.
EX8 Biostatistics, clinical trials C
EX9 Biostatistics, public health C Prefers more parsimonious model with interpretable parameters.
EX10 Cancer epidemiology, public health C Also suggests “versatile weighted log-rank test”
EX11 Statistics, public policy C
EX12 Biostatistics – Did not respond within timeframe
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“reason” should have a role in science. Similarly, EX8 ar-
gued “a conclusion should be reached based on a proper
consideration of the full evidence” and use scientific
principles—“full information from data should be ex-
tracted”. Indeed, rather than viewing it as “data-dredg-
ing” or “changing the endpoint”, EX8 described this
approach as just “using common sense”. EX9 felt the
lack of (complete) pre-specification a weakness, but not
“a violation of good scientific principles”. For “a major
and definitive screening trial ….. such regulatory con-
straints should not be the primary consideration” but in-
stead “approximating the truth as well as possible”. EX11
was not persuaded by the pre-specification argument
and claimed keeping a plan that is less preferable “turns
research rules into an irrational, mindless, and restrict-
ing obsession with methodological procedure”; “rules
have a purpose, but when the higher priority is under-
standing phenomena in a reasoned disciplined way…
then a compelling argument can be made to deviate
from them”. EX11 stated that no screening trial has
shown an immediate effect and appealed to the common
sense of the scientific audience; “we can discern the dif-
ference in attempts by a study team to game the analysis
to gain statistical significance, from a good faith effort to
apply a statistical technique that is more appropriate for
the data”. Different screening trials will have different re-
sults and delayed effects, all dependent on differing
facets of trial design and the cancer itself, the effects of
which are largely unknown until we do the study. “Point
is, we are still learning how to design and analyse RCT
screening trial data.”
Three of the eleven (EX2, EX3, EX1) believed that we
should retain the initial analysis approach (option A).
This was based on the pre-specification argument—
“avoids the appearance of trying to get a significant re-
sult by changing the test” (EX2), “maintains credibility in
the scientific community” (EX3), “most likely to be ac-
cepted as valid by the cancer research and policy com-
munity” (EX1). However, EX1 did suggest modifying the
pre-specified plan to limit analysis to only cancers diag-
nosed within the screening period.
Of the eight who suggested changing the pre-specified
analysis, five (EX7, EX8, EX9, EX10 and EX11) explicitly
selected approach C (using all acquired outcome data
and a model that allows for delayed effects). While there
were positive comments about the suggested RP model
(credibility due to pre-specification EX7, informative of
the screening effect over time EX9), none gave a clear
endorsement of this approach. The main reason was in-
terpretability (EX7, EX9, EX4, EX6). EX10 noted that
power was little studied under various “flavours” of non-
PHs, and suggested separating testing from estimation,
opting for a versatile weighted log-rank test for the
former. EX4 and EX6 formally indicated an alternative
option. EX6’s preference was for dividing the data into
yearly bins and estimating the HR in each, possibly with
some smoothing. EX6 argued extensively we should
avoid a single HR estimate, which will provide “a very
blurred, incomplete and misleading picture of how
much/little good screening did for the 100,000 partici-
pants screened, or of how much future women might
expect from a screening regimen based on these screen-
ing tools.” EX4 stated that the number needed to screen
was the most suitable measure for a screening study.
EX5 recommended a test based on the difference of re-
stricted mean survival times (RMST) which “does not
need any modelling and the results can be interpreted
easily clinically”.
None of the 11 responders chose approach B. This
was mainly because it did not use the full dataset. In
addition, there were concerns that it could lead to “un-
favourable early results” (important data) being censored
(EX11) and a “disconnected” HR (EX6).
Based on the feedback, we decided to change the pri-
mary analysis test for LTFU UKCTOCS. Table 3 sum-
marises the major pros and cons of available approaches
to dealing with non-PH in terms of tests. We used two
main criteria to choose the specific test—(1) minimal a
priori specification on the specific form of the mortality
difference over time (2) able to accommodate delayed ef-
fects while maintaining good power in a variety of po-
tential scenarios. Based on these criteria, we opted for
the Versatile test [16], suggested by EX10. The RP model
was retained to estimate absolute differences in disease-
specific mortality at 5, 10, 15 and 18 (our estimate of the
upper limit of reliable follow-up given administrative
censorship on 30 June 2020) years. Options A and B
were included as secondary analyses of the primary mor-
tality outcome. These amendments were incorporated
into the statistical analysis plan (20 February 2020),
which was endorsed by the independent TSC.
Discussion
Given the now large body of evidence of a delay in
mortality reduction in long-term cancer-screening
randomised trials, and the majority view of inde-
pendent statistical, epidemiological and screening
trial experts, we altered the approach for our pri-
mary mortality analysis for the LTFU from that used
for our 2014 analysis. The new approach allows for
a delayed effect in contrast to our previous analysis
which assumed a constant screening effect. There
were a variety of opinions on the specific test which
suggests an urgent need for consensus building on
how best to design, analyse and report mortality out-
comes in cancer-screening trials.
Our decision to change the statistical analysis plan for
extended follow-up is a significant decision. The large
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Table 3 Summary of pros and cons of potential statistical tests that could be used when there is a time varying mortality difference
(non-proportional hazards)
Method Pros Cons
Weighted log-rank test Not model-based Need to formally pre-specify the expected mor-
tality differences over time (functional form of
the HR) for the test to have statistical validity.
This may prove difficult given that differences
will depend on the natural history of the cancer,
screening strategy, number of screens, years of
follow-up, etc.
Known to improve power in situations of non-
PH.
There is an associated risk of mis-specifying the
form of the HR, and simulations suggest incor-
rectly assuming a late effect, for example, may
incur a greater penalty than assuming PHs
under early or late effects [33, 47].
Most widely used and established test for non-
PHs in clinical trials
Subjects’ deaths are given a differential (and
arbitrary) weighting which may be hard to
justify. A further conceptual problem with
weights based on the data is that if a trial
subsequently reports again, the weight allocated
to each event will change, likely significantly.
Flexible parametric model such as the Royston-
Parmar (RP) model (cubic splines) or fractional
polynomial (FP) survival model (joint test of all
screen arm related terms)
No need to pre-specify specific functional
form of the mortality effect
No precedence for use as primary analysis in
RCTs
Can mimic a non-PH function to almost arbi-
trary degree.
Flexibility makes it easy to over fit and include
random data artefacts.
Power properties not well known. Will lose
power with too many model parameters.
Allows one to accurately describe the hazards
and their ratio over time.
Need to pre-specify number of knots/degrees of
freedom and placement of knots for RP model.
FP model requires choice of selection of powers
and degree. Can be guided by information cri-
teria but then data dependent, and may reflect
artefacts.
Relatively easy to fit Test, as proposed, considers if mortality curves
are “different”. Significant result could
theoretically result from crossing curves, even
curves with no difference in area under the
curve.
Weibull model (with separate shape parameters
for group)
Can reflect simple time-varying differences in
mortality curves succinctly
Unlikely to capture more complex curves
sufficiently. All hazard functions must be
monotonic (constant decrease or increase)
Easy to fit
Cox model with time varying coefficient (TVC) Extension of Cox model, so perhaps more
readily acceptable given prior use
Need to pre-specify function of time that the
non-PHs apply to—usually a simple linear or log
function of time
Able to incorporate non-PHs without specifying
differences in mortality curves (functional form).
For example, choose linear function of time,
then time-varying effect could be linear decreas-
ing or increasing.
Interpretation not straightforward
Awkward and (very) time-consuming to fit (splits
data at each failure)
No definite agreement on test of significance.
Could be similar to the joint test on 2 degrees
of freedom.No need to consider baseline hazard function
Difference in restricted mean survival time
(RMST)
No need to be model-based, can use non-
parametric estimation.
Need to pre-specify choice of time restriction,
possibly including initial time t0, as well as final
time limit t1.
Can reflect any time-varying difference in mor-
tality - estimate of RMST difference graphically
corresponds to the difference in area between
the respective survival curves.
Do not need to speculate on particular form of
time varying difference in mortality. However
choice of time restriction may depend on
expectation of difference (HR functional form).
May be time consuming to estimate, including
standard error.
Gives a meaningful single summary estimate As the test looks for differences in area under
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majority of the published cancer-screening trials [17, 25,
26, 31, 33, 34] have retained the same primary mortality
analysis methodology for both their initial and extended
follow-up analysis (Table 1). The only exceptions we
found were the Two County trial which used negative
binomial regression [14] for follow-up analysis in place
of Mantel-Haenszel stratified risk-ratios [12] and the
Norwegian Colorectal Cancer Prevention Trial (NORC-
CAP) which changed the primary analysis from overall
population to subgroups based on gender [21]. In the
Two County trial, whilst no explanation was given, the
change was not substantive; both initial and follow-up
methods estimated risk ratios. For NORCCAP, “because
substantial heterogeneity existed between women and
men, the steering committee decided to present results
for women and men separately”, which may be argued
as a significant post hoc data-driven amendment. None
of the trials as far as we are aware sought independent
expert opinion. In contrast, we undertook an external
consultation. Although the independent expert panel
was not unanimous, the majority concluded that a
rational argument for revision outweighs that of proced-
ure and pre-specification, and recommended choosing
the most appropriate test that allows for a delayed effect.
We accepted the view of EX7 that one should “do what
you yourselves think is the most effective and secure
analysis of all your data, bearing in mind the current
state of information about the field.” There will be
debate about our decision, which we welcome, given the
broader implications.
A number of factors contribute to a delayed mortality
effect. In the early trial-years, the absolute death rates
are low as a result of eligibility criteria which exclude
women with cancer diagnosis. The time interval for an
individual to be diagnosed with cancer after joining the
trial and then dying of the disease also contributes to
the delay in separation of the mortality curves. Addition-
ally, the impact of screening on cancers detected at the
initial prevalence screen is reduced, as these are neces-
sarily more advanced when screen-detected compared to
screen-detected cancers in later years. The performance
of most screening strategies improves over time as the
number of screens accumulate and the teams involved
become more experienced. This is magnified when lon-
gitudinal biomarker algorithms are used, as they are
based on detecting change from baseline. Conversely,
the length of follow-up after end of screening may re-
duce the mortality difference as follow-up nears con-
clusion, as the longer the interval, the greater the
dilution of screen-detected cancers by cancers that
develop after the end of screening [34].
The PLCO colorectal [29] and ovarian [19] trials used
a test that has better power for the delayed effect de-
scribed above. Both used the weighted log-rank test,
which is perhaps the best known method for improving
power in such situations. However, it requires correctly
Table 3 Summary of pros and cons of potential statistical tests that could be used when there is a time varying mortality difference
(non-proportional hazards) (Continued)
Method Pros Cons
even with non-PHs the curve, survival curves that come back
together can result in a significant test result.
Combined test (of Cox test with a permutation
test based on RSMTs on 2 df)
Simulations suggest power not much lower
than Cox alone under PHs and more powerful
in more situations than joint test [33, 47].
Difficult to explain
Time-consuming to fit (permutation test).
Issues of RMST (see above)—choice of time
restriction
Enhanced power for early effect Simulations suggest not powerful for late effects
Joint test (of Cox proportional screen arm effect
+ Grambsch-Thurneau non-PH test on 2 df)
Test based on results of the Cox model (screen
arm effect and the Schoenfeld residuals), so
perhaps more readily acceptable given prior use
of the Cox model
Simulations suggest better under late effects but
not good power for early effects [33, 47].
Relatively simple test (with degree of
intuitiveness), but more powerful than just
screen arm effect under non-PHs
Combination tests such as Versatile Test
(maximum test statistic of 3 weighted tests—
early, PHs, late effects) or “max-combo” (also
includes “middle” effects)
Not model-based Appears complicated (need for reference to a
correlated multivariate z-distribution for test
statistic)
Provides good power in all situations, covers
bases with small price in efficiency
Not the most powerful test.
Best choice if one wants to be agnostic of
specifying the time varying mortality difference
Can feasibly reject the null hypothesis both in
favour of the study arm and of the control arm
using the same data.
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anticipating the specific form of the mortality difference
over time, which will depend on the natural history of
the cancer, screening strategy, number and frequency of
screens and years of follow-up. We have chosen the Ver-
satile test [42], introduced in 2016, which does not re-
quire pre-specification of the mortality difference over
time. It combines three (weighted) log-rank tests appro-
priate for capturing early effects, PH and delayed effects,
respectively. It is therefore versatile enough to maintain
good power in all potential scenarios, rather than opti-
mal in any given scenario.
Unlike other trials, including the PLCO colorectal [29]
and ovarian [19] trials, who measured the screening
effect using a single “averaged” rate-ratio, we will use a
flexible parametric model to estimate absolute differ-
ences in disease-specific mortality at 5, 10, 15 and 18
years. This is in keeping with the growing view that to
adequately describe what might be achieved with a
particular cancer screening strategy, a more comprehen-
sive set of time-specific measures needs to be reported.
Hanley et al. has extensively re-analysed cancer screen-
ing trial data and shown that a one-number summary
measure systematically dilutes the estimate of mortality
reduction that results from screening [2]. In the most re-
cent re-analysis involving breast cancer screening data
from Funen, Denmark, the average mortality reduction
was 18% using a PH model and ranged from 0 to 30%
when a non-PH model was used that considered the im-
pact at different points over time. The reductions were
largest for periods where sufficient time had elapsed for
the impact to manifest [48]. It is important to note that
our estimates of screening efficacy will not necessarily
capture the screening effect of a screening program,
where participants would likely start screening at age 50
and continue for possibly 25 years. However, once
results of our primary analysis are published, it will be
possible for groups around the world to use our data to
model effectiveness over a longer timeframe and in
multiple settings.
The key strength of our approach is the independ-
ent and transparent process we have adopted to ad-
dress a challenging issue and the criteria we used to
choose a new specific approach. This involved accom-
modating delayed effects while maintaining good
power in a variety of potential scenarios and requiring
minimal a priori speculation on the specific form of
the mortality difference over time. A limitation is that
given the orthodoxy surrounding pre-specification for
analysis of trials, we have retained the original Cox
model with an averaged HR over time as an estimate
for our secondary analysis.
The screening community is only beginning to under-
stand the challenges posed by long-term cancer-
screening trials. Mortality reductions may have been
underestimated across cancer types by not considering
their timing. Given the importance of early detection in
many national cancer strategies, we hope our report will
accelerate much needed consensus building on how best
to design, analyse and report trials testing cancer screen-
ing strategies—as it is clear our currently accepted and
widely used methods are insufficient. We also hope it
will encourage debate and transparency on how
advances in understanding and new analytical methods
can be evaluated and incorporated into long-term trials.
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